Patents by Inventor Romain Verpillot

Romain Verpillot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220196682
    Abstract: The invention has for object an in vitro method for performing a differential diagnosis of neurodegenerative diseases selected from early stage of Alzheimer's disease, advanced stage of Alzheimer's disease, mental depression, dementia with Lewy bodies, frontotemporal dementia, and/or vascular dementia; said method being performed in a subject presenting signs of dementia and comprising the steps of (a) determining at least five criteria of said subject, said at least five criteria comprising the age of said subject, a score of said subject to a questionnaire adapted for screening cognitive function, a dopamine, adrenaline and noradrenaline concentration in a blood sample of said subject, (b) comparing said noradrenaline concentration to a predetermined threshold, (c) calculating one global note in relation with each neurodegenerative disease and (d) determining whether said subject suffers from one or more neurodegenerative diseases.
    Type: Application
    Filed: April 17, 2020
    Publication date: June 23, 2022
    Applicant: SAS ALZOHIS
    Inventors: Romain VERPILLOT, Hervé THIRIEZ, Rudy BEAUJEAN
  • Publication number: 20210293831
    Abstract: The invention is directed to an in vitro method for performing a differential diagnosis of neurodegenerative diseases in a subject, said subject being selected among subjects suffering from Alzheimer's disease, mental depression, dementia with Lewy Body, frontotemporal dementia, and/or vascular dementia. Said method comprises the steps of: (a) determining at least five criteria of said subject, (b) comparing said at least five criteria of said subject with reference values by calculating a global note in relation with each neurodegenerative disease, and (c) determining whether said subject suffers from Alzheimer's disease, mental depression, dementia with Lewy Body, frontotemporal dementia, vascular dementia or mixed dementia.
    Type: Application
    Filed: July 22, 2019
    Publication date: September 23, 2021
    Applicant: ALZOHIS
    Inventors: Romain Verpillot, Hervé Thirlez
  • Publication number: 20210249131
    Abstract: The invention is directed to an in vitro method for performing a differential diagnosis of neurodegenerative diseases in a subject, said subject being selected among subjects suffering from Alzheimer's disease, menial depression, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, progressive supranuclear palsy, and/or Parkinson's disease with dementia. Said method comprises the steps of: (a) determining at least five criteria of said subject, (b) comparing said at least five criteria of said subject with reference values by calculating a global note in relation with each neurodegenerative disease, and (c) determining whether said subject suffers from Alzheimer's disease, mental depression, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, progressive supranuclear palsy, Parkinson's disease with dementia or mixed dementia.
    Type: Application
    Filed: June 6, 2019
    Publication date: August 12, 2021
    Applicant: ALZOHIS
    Inventors: Romain Verpillot, Hervé Thiriez
  • Patent number: 9606113
    Abstract: The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, wherein the level of each of at least two catecholamines is measured in a sample of biological fluid from said subject.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: March 28, 2017
    Assignees: Centre National De La Recherche Scientifique (C.N.R.S), Universite Paris-Sud 11
    Inventors: Myriam Taverna, Romain Verpillot, Markus Otto, Hans Klafki
  • Publication number: 20140370529
    Abstract: The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, wherein the level of each of at least two catecholamines is measured in a sample of biological fluid from said subject.
    Type: Application
    Filed: September 17, 2012
    Publication date: December 18, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), Universite Paris- Sud 11
    Inventors: Myriam Taverna, Romain Verpillot, Markus Otto, Hans Klafki